Homocysteine and risk of recurrent stroke

Stroke

Volumn 34, Issue 5, 2003, Pages 1258-1261

  Boysen, Gudrun ^a   Brander, Thomas ^b   Christensen, Hanne ^b   Gideon, Rolf ^b   Truelsen, Thomas ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NONE

Author keywords

Cerebral hemorrhage; Cerebral infarction; Cerebrovascular disorders; Intracerebral hemorrhage; Risk factors

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERTENSION; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; RISK; RISK FACTORS; SMOKING;

EID: 0038643400     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000069017.78624.37     Document Type: Article

References (32)

1. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386-389.
2. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Int Med. 1994;236:603-617.
3. Selhub J, Jacques PF, Bostom, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med. 1995;332:286-291.
4. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994;236:633-641.
5. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
6. Kittner SJ, Giles WH, Macko RF, Hebel JR, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sloan MA, Sherwin R, et al. Homocyst(e)ine and risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. Stroke. 1999;30:1554-1560.
7. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
8. Møller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jørgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Lab Invest. 2000;60:491-500.
9. Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. Am J Cardiol. 2000;86:585-586.
10. Ford ES, Smith SJ, Stoup DF, Steinberg KK, Mueller PW, Thacker SB. Homocysteine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002;31:59-70.
11. Fallon UB, Elwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD. Homocysteine and ischaemic stroke in men: the Caerphilly Study. J Epidemiol Community Health. 2001;55:91-96.
12. Stampfer MJ, Malinow MR, Willett WC, Nowcomer LM, Upson B, Ullmann D. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
13. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoproteina concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
14. Perry IF, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
15. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PWF, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med. 1999;131:352-355.
16. Bots ML, Lauber LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam study. J Intern Med. 1997;242:339-347.
17. Rasmussen K, Møller J. Total homocysteine measurement in clinical practice. Ann Clin Biochem. 2000;37:627-648.
18. TOAST Publications Committee. Low molecular weight heparinoid, Org 10172, danaparoid and outcome after acute ischemic stroke. JAMA. 1998; 279:1265-1272.
19. Lindenstrøm E, Boysen G, Christiansen LW, á Roger-Hansen B, Nielsen BW. Reliability of Scandinavian Stroke Scale. Cerebrovasc Dis. 1991;1: 103-107.
20. Del Ser T, Barba R, Herranz AS, Seijas V, López-Manglano C, Domingo J, Pondal M. Hyperhomocyst(e)inemia is a risk factor of secondary vascular events in stroke patients. Cerebrovasc Dis. 2001;12:91-98.
21. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
22. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
23. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000;31:1069-1075.
24. Tan NC, Venketasubramanian N, Saw SM, Tjia HT. Hyperhomocyst(e)inemia and risk of ischemic stroke among young Asian adults. Stroke. 2002;33:1956-1962.
25. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2: 386-389.
26. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation. 1993;87:1107-1113.
27. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Siligsohn U, Inbal A. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke. 2001;32:2753-2758.
28. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L. Am J Hypertens. 2000;13:105-110.
29. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288:2015-2022.
30. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-1208.
31. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew OC, Stampfer M, Toole JF. Vitamin intervention for stroke prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001;20:16-25.
32. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rational and design of an international, large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.